Unsaturated nitrogen heterocyclic compounds useful as pde10 inhibitors

Abstract

Unsaturated nitrogen heterocyclic compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

What is claimed is: 
     
         1 . A compound of formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein:
 X 1  is N or CR 6 ; 
 X 2  is N or CR 2 ; 
 X 3  is N or CR 3 ; 
 X 4  is N or CR 6 ; 
 X 5  is N or CR 6 ; 
 
         wherein 1 to 2 of X 1 , X 2 , X 3 , X 4  and X 5  are N;
 R 1  is halo, C 1-8 alk, C 1-4 haloalk, —OR c , —N(R a )C(═O)R b , —C(═O)R a , —C(═O)R c , —C(═O)—O—R a , —NR a R c , —N(R c )C(═O)R b , —N(R a )C(═O)R c , —C(═O)NR a R b , —C(═O)NR a R c , or C 0-4 alk-L 1 ; wherein said C 1-8 alk group is substituted by 0, 1, 2 or 3 groups which are halo, C 1-3 haloalk, —OH, —OC 1-4 alk, —NH 2 , —NHC 1-4 alk, —OC(═O)C 1-4 alk, or —N(C 1-4 alk)C 1-4 alk; 
 Y is a C 0-4 alk, —C(═O), SO, or SO 2 ; 
 each R 2  and R 3  is independently R 1 , H, halo, CN, OH, —OC 1-4 alk, C 1-4 alk, C 1-4 haloalk, —C 1-6 alkOR a , —C(═O)C 1-4 alk, —C(═O)NR a R a , —C 0-4 alkNH—C(═O)R a , or R c ; 
 or alternatively the ring containing X 1 , X 2 , X 3 , X 4  and X 5  can be fused to ring A, ring B, or ring C; each having the formula: 
 
       
       
         
           
           
               
               
           
         
       
       wherein each said ring A, ring B, or ring C is a fused 4- to 6-membered-saturated, -partially saturated, or -unsaturated-carbocyclic or -heterocyclic ring containing 0, 1, 2, or 3 heteroatoms; and is substituted by 0, 1, or 2 R 10  groups;
   R 4a  is H, OH, halo, C 1-4 alk, or C 1-4 haloalk;   R 4b  is halo, CN, OH, OC 1-4 alk, C 1-4 alk, C 1-4 haloalk, or oxo;   R 5  is —C 1-6 alkOR a , 5- to 6-membered heteroaryl, unsaturated 9- to 10-membered bicyclo-heterocyclic ring, or 11- to 15-membered tricyclo-heterocyclic ring; R 5  ring is substituted by 0, 1, 2, 3, or 4 R 8  groups;   R 6  is independently R 1 , H, halo, CN, OH, OC 1-4 alk, C 1-4 alk or C 1-4 haloalk;   m is 0, 1, 2, 3, or 4;   each of p and q is independently 0, 1, 2, 3, 4, 5, or 6; wherein the sum of p and q is 2 to 6;   the ring containing p and q contains 0, 1, or 2 double bonds;   R a  is independently H or R b ;   R b  is independently phenyl, benzyl, or C 1-6 alk, wherein said phenyl, benzyl, and C 1-6 alk are substituted by 0, 1, 2 or 3 substituents which are, independently, halo, C 1-4 alk, C 1-3 haloalk, —OH, —OC 1-4 alk, —NH 2 , —NHC 1-4 alk, —OC(═O)C 1-4 alk, or —N(C 1-4 alk)C 1-4 alk;   R c  is C 0-4 alk-L 2 ;   each L 1  is independently a carbon-linked or nitrogen-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or a saturated, partially-saturated or unsaturated 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic ring, said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms which are O or S; L 1  is independently substituted by 0, 1, 2 or 3 R 9  groups;   each L 2  is independently a carbon-linked or nitrogen-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or a saturated, partially-saturated or unsaturated 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic ring, said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms which are O or S; L 2  is independently substituted by 0, 1, 2 or 3 R 11  groups;   R 8  is halo, CN, OH, OC 1-4 alk, C 1-4 alk, C 1-4 haloalk, OC 1-4 haloalk, —C(═O)R b , —C(═O)R c , —C(═O)NHR b , —C(═O)NHR c , —S(═O) 2 R b , —S(═O) 2 R c , —S(═O) 2 NR a R a , R b , R c , NO 2 , OR b , or OR c ;   R 9  is halo, C 1-6 alk, C 1-4 haloalk, —OR a , —OC 1-4 haloalk, CN, —C(═O)R b , —C(═O)OR a , —C(═O)NR a R a , —C(═NR a )NR a R a , —OC(═O)R b , —OC(═O)NR a R a , —OC 1-6 alkNR a R a , —OC 1-6 alkOR a , —SR a , —S(═O)R b , —S(═O) 2 R b , —S(═O) 2 NR a R a , —NR a R a , —N(R a )C(═O)R b , —N(R a )C(═O)OR b , —N(R a )C(═O)NR a R a , —N(R a )C(═NR a )NR a R a , —N(R a )S(═O) 2 R b , —N(R a )S(═O) 2 NR a R a , —NR a C 1-6 alkNR a R a , —NR a C 1-6 alkOR a , —C 1-6 alkNR a R a , —C 1-6 alkOR a , —C 1-6 alkN(R a )C(═O)R b , —C 1-6 alkOC(═O)R b , —C 1-6 alkC(═O)NR a R a , —C 1-6 alkC(═O)OR a , oxo, or R c ;   R 10  is oxo, C 1-6 alk, C 1-3 haloalk, —OH, —OC 1-4 alk, —NH 2 , —NHC 1-4 alk, —OC(═O)C 1-4 alk, or —N(C 1-4 alk)C 1-4 alk; and   R 11  is halo, C 1-6 alk, C 1-4 haloalk, —OR a , —OC 1-4 haloalk, CN, —C(═O)R b , —C(═O)OR a , —C(═O)NR a R a , —C(═NR a )NR a R a , —OC(═O)R b , —OC(═O)NR a R a , —OC 1-6 alkNR a R a , —OC 1-6 alkOR a , —SR a , —S(═O)R b , —S(═O) 2 R b , —S(═O) 2 NR a R a , —NR a R a , —N(R a )C(═O)R b , —N(R a )C(═O)OR b , —N(R a )C(═O)NR a R a , —N(R a )C(═NR a )NR a R a , —N(R a )S(═O) 2 R b , —N(R a )S(═O) 2 NR a R a , —NR a C 1-6 alkNR a R a , —NR a C 1-6 alkOR a , —C 1-6 alkNR a R a , —C 1-6 alkOR a , —C 1-6 alkN(R a )C(═O)R b , —C 1-6 alkOC(═O)R b , —C 1-6 alkC(═O)NR a R a , —C 1-6 alkC(═O)OR a , or oxo.   
 
     
     
         2 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein the group 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         3 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein the group 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         4 . The compound according to  claim 3 , or a pharmaceutically acceptable salt thereof, wherein each of said Ring A, Ring B, and Ring C is a fused 4- to 6-membered-saturated, -partially saturated, or -unsaturated-carbocyclic which are fused phenyl, cyclobutyl, cyclopentyl, or cyclohexyl; said Ring A, Ring B, and Ring C is substituted by 0, 1, or 2 R 10  groups which are oxo, C 1-6 alk, C 1-3 haloalk, —OH, —OC 1-4 alk, —NH 2 , —NHC 1-4 alk, —OC(═O)C 1-4 alk, or —N(C 1-4 alk)C 1-4 alk. 
     
     
         5 . The compound according to  claim 3 , or a pharmaceutically acceptable salt thereof, wherein each of said Ring A, Ring B, and Ring C is a fused 5-membered-saturated, -partially saturated, or -unsaturated-heterocyclic ring which are fused furanyl, thiophenyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, dioxolanyl, oxazolyl, thiazolyl, isothiazolyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, isoxazolyl, or isothiazolyl; said Ring A, Ring B, and Ring C is substituted by 0, 1, or 2 R 10  groups which are oxo, C 1-6 alk, C 1-3 haloalk, —OH, —OC 1-4 alk, —NH 2 , —NHC 1-4 alk, —OC(═O)C 1-4 alk, or —N(C 1-4 alk)C 1-4 alk. 
     
     
         6 . The compound according to  claim 3 , or a pharmaceutically acceptable salt thereof, wherein each of said Ring A, Ring B, and Ring C is a fused 6-membered-saturated, -partially saturated, or -unsaturated-heterocyclic ring which are fused pyranyl, pyridinyl, piperidinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, pyridazinyl, pyrazinyl, or piperazinyl; said Ring A, Ring B, and Ring C is substituted by 0, 1, or 2 R 10  groups which are oxo, C 1-6 alk, C 1-3 haloalk, —OH, —OC 1-4 alk, —NH 2 , —NHC 1-4 alk, —OC(═O)C 1-4 alk, or —N(C 1-4 alk)C 1-4 alk. 
     
     
         7 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein each of p and q is independently 1. 
     
     
         8 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein each of p and q is independently 2. 
     
     
         9 . The compound according to  claim 8 , or a pharmaceutically acceptable salt thereof, wherein the ring containing p and q contains 0 or 1 double bond. 
     
     
         10 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein the sum of p and q is 3; and the ring containing p and q contains 0 or 1 double bond. 
     
     
         11 . The compound according to  claim 9 , or a pharmaceutically acceptable salt thereof, wherein R 4b  is oxo and m is 1. 
     
     
         12 . The compound according to  claim 11 , or a pharmaceutically acceptable salt thereof, wherein R 5  is unsaturated 10-membered bicyclo-heterocyclic ring; wherein each R 5  ring is substituted by 0, 1, or 2 R 8  groups. 
     
     
         13 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein the group 
       
         
           
           
               
               
           
         
       
       wherein each 
       
         
           
           
               
               
           
         
       
       is substituted by 0, 1, or 2 R 10  groups. 
     
     
         14 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 1 or 2. 
     
     
         15 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1  is —NR a R c , —OR c  or —C 0-4 alk-L 1 . 
     
     
         16 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein L 1  is a carbon-linked-saturated or partially-saturated 3-, 4-, 5-, 6-, or 7-membered monocyclic ring, wherein each said ring contains 0, 1, or 2 N atoms and 0 or 1 O atoms, and wherein each said L 1  is substituted by 0, 1 or 2 R 9  groups which are F, Cl, Br, C 1-6 alk, —OR a , CN, —C(═O)R b , C(═O)OR a , —C(═O)NR a R a , —SR a , —S(═O)R b , —S(═O) 2 R b , —NR a R a , —N(R a )C(═O)R b , —N(R a )C(═O)OR b , —C 1-6 alkOR a , —C 1-6 alkN(R a )C(═O)R b , —C 1-6 alkOC(═O)R b , —C 1-6 alkC(═O)NR a R a , —C 1-6 alkC(═O)OR a , oxo, or R c . 
     
     
         17 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein L 1  is a carbon-linked-saturated or partially-saturated 5- to 6-membered monocyclic ring, wherein each said ring contains 0, 1, or 2 N atoms and 0 or 1 O atoms, and wherein each said L 1  is substituted by 0, 1 or 2 R 9  groups which are F, Cl, Br, C 1-6 alk, —OR a , CN, —C(═O)R b , C(═O)OR a , —C(═O)NR a R a , —SR a , —S(═O)R b , —S(═O) 2 R b , —NR a R a , —N(R a )C(═O)R b , —N(R a )C(═O)OR b , —C 1-6 alkOR a , —C 1-6 alkN(R a )C(═O)R b , —C 1-6 alkOC(═O)R b , —C 1-6 alkC(═O)NR a R a , —C 1-6 alkC(═O)OR a , oxo, or R c . 
     
     
         18 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein L 1  is a carbon-linked-unsaturated 5- to 6-membered monocyclic ring, wherein each said ring contains 0, 1, or 2 N atoms and 0 or 1 O atoms, and wherein each said L 1  is substituted by 0, 1 or 2 R 9  groups which are F, Cl, Br, C 1-6 alk, —OR a , CN, —C(═O)R b , C(═O)OR a , —C(═O)NR a R a , —SR a , —S(═O)R b , —S(═O) 2 R b , —NR a R a , —N(R a )C(═O)R b , —N(R a )C(═O)OR b , —C 1-6 alkOR a , —C 1-6 alkN(R a )C(═O)R b , —C 1-6 alkOC(═O)R b , —C 1-6 alkC(═O)NR a R a , —C 1-6 alkC(═O)OR a , oxo, or R c . 
     
     
         19 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein L 1  is a carbon-linked-saturated, partially-saturated or unsaturated 6-, 7-, 8-, 9-, or 10-membered bicyclic ring, wherein each said ring contains 0, 1, or 2 N atoms and 0 or 1 O atoms, and wherein each said L 1  is substituted by 0, 1 or 2 R 9  groups which are F, Cl, Br, C 1-6 alk, —OR a , CN, —C(═O)R b , C(═O)OR a , —C(═O)NR a R a , —SR a , —S(═O)R b , —S(═O) 2 R b , —NR a R a , —N(R a )C(═O)R b , —N(R a )C(═O)OR b , —C 1-6 alkOR a , —C 1-6 alkN(R a )C(═O)R b , —C 1-6 alkOC(═O)R b , —C 1-6 alkC(═O)NR a R a , —C 1-6 alkC(═O)OR a , oxo, or R c . 
     
     
         20 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein L 1  is a nitrogen-linked saturated, partially-saturated or unsaturated 4-, 5-, 6-, or 7-membered monocyclic ring, wherein said ring contains 0, 1, 2, 3, or 4 N atoms and 0 or 1 O atoms, and wherein each said L 1  is substituted by 0, 1 or 2 R 9  groups which are F, Cl, Br, C 1-6 alk, —OR a , CN, —C(═O)R b , C(═O)OR a , —C(═O)NR a R a , —SR a , —S(═O)R b , —S(═O) 2 R b , —NR a R a , —N(R a )C(═O)R b , —N(R a )C(═O)OR b , —C 1-6 alkOR a , —C 1-6 alkN(R a )C(═O)R b , —C 1-6 alkOC(═O)R b , —C 1-6 alkC(═O)NR a R a , —C 1-6 alkC(═O)OR a , oxo, or R c . 
     
     
         21 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein L 1  is a nitrogen-linked saturated, partially-saturated or unsaturated 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic ring, wherein each said ring contains 0, 1, or 2 N atoms and 0 or 1 O atoms, and wherein each said L 1  is substituted by 0, 1 or 2 R 9  groups which are F, Cl, Br, C 1-6 alk, —OR a , CN, —C(═O)R b , C(═O)OR a , —C(═O)NR a R a , —SR a , —S(═O)R b , —S(═O) 2 R b , —NR a R a , —N(R a )C(═O)R b , —N(R a )C(═O)OR b , —C 1-6 alkOR a , —C 1-6 alkN(R a )C(═O)R b , —C 1-6 alkOC(═O)R b , —C 1-6 alkC(═O)NR a R a , —C 1-6 alkC(═O)OR a , oxo, or R c . 
     
     
         22 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein L 1  is −3-azabicyclo[3.1.0]hexanyl, azetidinyl, indolyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazolyl, piperazinonyl, piperidinyl, pyrrolidinyl, dihydropyranyl, tetrahydropyridinyl, octahydropyrrolo[3,4-c]pyrrolyl, tetrahydroisoquinolinyl, each of which is substituted by 0, 1 or 2 R 9  groups which are F, Cl, Br, C 1-6 alk, —OR a , CN, —C(═O)R b , C(═O)OR a , —C(═O)NR a R a , —SR a , —S(═O)R b , —S(═O) 2 R b , —NR a R a , —N(R a )C(═O)R b , —N(R a )C(═O)OR b , —C 1-6 alkOR a , —C 1-6 alkN(R a )C(═O)R b , —C 1-6 alkOC(═O)R b , —C 1-6 alkC(═O)NR a R a , —C 1-6 alkC(═O)OR a , oxo, or R c . 
     
     
         23 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1  is: Cl; Br; —C≡C—CH 3 ; —NH—CH(CH 3 ) 2 ; —NHCH 2 CH 2 OCH 3 ; —NHCH 2 CH 2 OH; 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         24 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1  is 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         25 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1  is: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         26 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 2  and R 3  is independently H, F, Cl, Br, CN, OH, OC 1-4 alk, C 1-4 alk or C 1-4 haloalk. 
     
     
         27 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 6  is H, F, or C 1-4 alk. 
     
     
         28 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4a  is H, F, OH, or methyl. 
     
     
         29 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4b  is oxo and m is 1. 
     
     
         30 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4a  is H and m is 0. 
     
     
         31 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5  is pyridinyl. 
     
     
         32 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5  is unsaturated 9- to 10-membered bicyclo-heterocyclic ring. 
     
     
         33 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5  is 11- to 15-membered tricyclo-heterocyclic ring. 
     
     
         34 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein the group —Y—R 5  is: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       wherein each R 5  is substituted by 1 or 2 R 8  groups. 
     
     
         35 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein the group —Y—R 5  is: 
       
         
           
           
               
               
           
         
       
       wherein each R 5  is substituted by 1 or 2 R 8  groups. 
     
     
         36 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein the group —Y—R 5  is: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         37 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y is a bond or —C(═O). 
     
     
         38 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y is a bond. 
     
     
         39 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 8  is independently F, Br, Cl, CF 3 , methyl, methoxy, or CN. 
     
     
         40 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein R a  is H or C 1-6 alk substituted by 0 or 1 —OH, —OC 1-4 alk, —OC(═O)C 1-4 alk, or —N(C 1-4 alk)C 1-4 alk. 
     
     
         41 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein R c  is a C 0-4 alk-carbon-linked saturated, partially-saturated or unsaturated 3-, 4-5-, or 6-membered monocyclic ring containing 0, 1, or 2 N atoms and 0 or 1 atom which are O or S, each R c  is substituted by 0 or 1 R 11  groups which are independently F, C 1-6 alk, C 1-4 haloalk, or —OR a . 
     
     
         42 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, wherein R c  is pyridyl, phenyl, or 1,2,4-oxadiazolyl. 
     
     
         43 . A compound of formula II: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, wherein:
 Ring D is -L 1 ; 
 X 1  is N or CR 6 ; 
 X 2  is N or CR 2 ; 
 X 3  is N or CR 3 ; 
 X 4  is N or CR 6 ; 
 wherein 1 to 2 of X 1 , X 2 , X 3 , and X 4  are N; 
 Y is a C 0-4 alk, —C(═O), SO, or SO 2 ; 
 each R 2  and R 3  is independently H, halo, CN, OH, —OC 1-4 alk, C 1-4 alk, C 1-4 haloalk, —C 1-6 alkOR a , —C(═O)C 1-4 alk, —C(═O)NR a R a , —C 0-4 alkNH—C(═O)R a , or R c ; 
 or alternatively the ring containing X 1 , X 2 , X 3 , X 4  and X 5  can be fused to ring A, ring B, or ring C; having the formula: 
 
       
         
           
           
               
               
           
         
       
       wherein each said ring A, ring B, or ring C is a fused 4- to 6-membered-saturated, -partially saturated, or -unsaturated-carbocyclic or -heterocyclic ring containing 0, 1, 2, or 3 heteroatoms; and is substituted by 0, 1, or 2 R 10  groups;
 R 4a  is H, OH, halo, C 1-4 alk, or C 1-4 haloalk; 
 R 4b  is halo, CN, OH, OC 1-4 alk, C 1-4 alk, C 1-4 haloalk, or oxo; 
 R 5  is pyridinyl or unsaturated 9- to 10-membered bicyclo-heterocyclic ring; wherein each R 5  is substituted by 0, 1, 2 or 3 R 8  groups; 
 R 6  is independently H, halo, CN, OH, OC 1-4 alk, C 1-4 alk or C 1-4 haloalk; 
 m is 0, 1, 2, 3, or 4; 
 each of p and q is independently 0, 1, 2, 3, 4, 5, or 6; wherein the sum of p and q is 2 to 6; 
 the ring containing p and q contains 0, 1, or 2 double bonds; 
 R a  is independently H or R b ; 
 R b  is independently phenyl, benzyl, or C 1-6 alk, wherein said phenyl, benzyl, or C 1-6 alk substituted by 0, 1, 2 or 3 substituents which are, independently, halo, C 1-4 alk, C 1-3 haloalk, —OH, —OC 1-4 alk, —NH 2 , —NHC 1-4 alk, —OC(═O)C 1-4 alk, or —N(C 1-4 alk)C 1-4 alk; 
 R c  is C 0-4 alk-L 2 ; 
 each L 1  is independently a carbon-linked or nitrogen-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or a saturated, partially-saturated or unsaturated 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms which are O or S; wherein each L 1  is independently substituted by 0, 1, 2 or 3 R 9  groups; 
 each L 2  is independently a carbon-linked or nitrogen-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or a saturated, partially-saturated or unsaturated 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms which are O or S; wherein each L 2  is independently substituted by 0, 1, 2 or 3 R 11  groups; 
 R 8  is halo, CN, OH, OC 1-4 alk, C 1-4 alk, C 1-4 haloalk, OC 1-4 haloalk, —C(═O)R b , —C(═O)R c , —C(═O)NHR b , —C(═O)NHR c , —S(═O) 2 R b , —S(═O) 2 R c , —S(═O) 2 NR a R a , R b , R c , NO 2 , OR b , or OR c ; 
 R 9  is F, Cl, Br, C 1-6 alk, C 1-4 haloalk, —OR a , —OC 1-4 haloalk, CN, —C(═O)R b , —C(═O)OR a , —C(═O)NR a R a , —C(═NR a )NR a R a , —OC(═O)R b , —OC(═O)NR a R a , —OC 1-6 alkNR a R a , —OC 1-6 alkOR a , —SR a , —S(═O)R b , —S(═O) 2 R b , —S(═O) 2 NR a R a , —NR a R a , —N(R a )C(═O)R b , —N(R a )C(═O)OR b , —N(R a )C(═O)NR a R a , —N(R a )C(═NR a )NR a R a , —N(R a )S(═O) 2 R b , —N(R a )S(═O) 2 NR a R a , —NR a C 1-6 alkNR a R a , —NR a C 1-6 alkOR a , —C 1-6 alkNR a R a , —C 1-6 alkOR a , —C 1-6 alkN(R a )C(═O)R b , —C 1-6 alkOC(═O)R b , —C 1-6 alkC(═O)NR a R a , —C 1-6 alkC(═O)OR a , oxo, or R c ; 
 R 10  is oxo, C 1-6 alk, C 1-3 haloalk, —OH, —OC 1-4 alk, —NH 2 , —NHC 1-4 alk, —OC(═O)C 1-4 alk, or —N(C 1-4 alk)C 1-4 alk; and 
 R 11  is F, Cl, Br, C 1-6 alk, C 1-4 haloalk, —OR a , —OC 1-4 haloalk, CN, —C(═O)R b , —C(═O)OR a , —C(═O)NR a R a , —C(═NR a )NR a R a , —OC(═O)R b , —OC(═O)NR a R a , —OC 1-6 alkNR a R a , —OC 1-6 alkOR a , —SR a , —S(═O)R b , —S(═O) 2 R b , —S(═O) 2 NR a R a , —NR a R a , —N(R a )C(═O)R b , —N(R a )C(═O)OR b , —N(R a )C(═O)NR a R a , —N(R a )C(═NR a )NR a R a , —N(R a )S(═O) 2 R b , —N(R a )S(═O) 2 NR a R a , —NR a C 1-6 alkNR a R a , —NR a C 1-6 alkOR a , —C 1-6 alkNR a R a , —C 1-6 alkOR a , —C 1-6 alkN(R a )C(═O)R b , —C 1-6 alkOC(═O)R b , —C 1-6 alkC(═O)NR a R a , —C 1-6 alkC(═O)OR a , or oxo. 
 
     
     
         44 . The compound according to  claim 43 , wherein the group 
       
         
           
           
               
               
           
         
       
       is azetidinyl, pyrrolidinyl, piperidinyl, or azepanyl. 
     
     
         45 . The compound according to  claim 43 , having the formula: 
       
         
           
           
               
               
           
         
       
     
     
         46 . The compound according to  claim 43 , having the formula: 
       
         
           
           
               
               
           
         
       
     
     
         47 . The compound according to  claim 43 , having the formula: 
       
         
           
           
               
               
           
         
       
     
     
         48 . The compound according to  claim 47 , wherein R 4b  is OXO; m is 1; and R 5  is unsaturated 10-membered bicyclo-heterocyclic ring; wherein each R 5  ring is substituted by 0, 1, or 2 R 8  groups. 
     
     
         49 . The compound according to  claim 47 , having the formula: 
       
         
           
           
               
               
           
         
         wherein m is 0; and R 5  is unsaturated 10-membered bicyclo-heterocyclic ring; wherein each R 5  ring is substituted by 0, 1, or 2 R 8  groups. 
       
     
     
         50 . The compound according to  claim 45 , wherein the group —Y—R 5  is: 
       
         
           
           
               
               
           
         
       
       Y is a bond; wherein each R 5  is substituted by 1 or 2 R 8  groups; and R 8  is independently F, Cl, Br, methyl, ethyl, isopropyl, methoxy, CN, CF 3 , OH, or OCF 3 . 
     
     
         51 . The compound according to  claim 46 , wherein the group —Y—R 5  is: 
       
         
           
           
               
               
           
         
       
       Y is a bond; wherein each R 5  is substituted by 1 or 2 R 8  groups; and R 8  is independently F, Cl, Br, methyl, ethyl, isopropyl, methoxy, CN, CF 3 , OH, or OCF 3 . 
     
     
         52 . The compound according to  claim 47 , wherein the group —Y—R 5  is: 
       
         
           
           
               
               
           
         
       
       Y is a bond; wherein each R 5  is substituted by 1 or 2 R 8  groups; and R 8  is independently F, Cl, Br, methyl, ethyl, isopropyl, methoxy, CN, CF 3 , OH, or OCF 3 . 
     
     
         53 . The compound according to  claim 48 , wherein the group —Y—R 5  is: 
       
         
           
           
               
               
           
         
       
       Y is a bond; wherein each R 5  is substituted by 1 or 2 R 8  groups; and R 8  is independently F, Cl, Br, methyl, ethyl, isopropyl, methoxy, CN, CF 3 , OH, or OCF 3 . 
     
     
         54 . A method of treating conditions that may be treated with PDE10 inhibitors comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to  claim 1 , or a pharmaceutically acceptable salt thereof. 
     
     
         55 . The method according to  claim 54  wherein said condition is psychoses, Parkinson's disease, dementias, obsessive compulsive disorder, tardive dyskinesia, choreas, depression, mood disorders, impulsivity, drug addiction, attention deficit/hyperactivity disorder (ADHD), depression with parkinsonian states, personality changes with caudate or putamen disease, dementia and mania with caudate and pallidal diseases, or compulsions with pallidal disease. 
     
     
         56 . A method of treating conditions that may be treated with PDE10 inhibitors comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to  claim 43 , or a pharmaceutically acceptable salt thereof. 
     
     
         57 . The method according to  claim 56  wherein said condition is schizophrenia, Huntington disease, obesity, bipolar disorder, or obsessive-compulsive disorder. 
     
     
         58 . A pharmaceutical composition comprising a compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 
     
     
         59 . The compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, which is:
 (1H-Benzoimidazol-2-yl)-[3-(3-phenyl-pyridin-2-yl)-azetidin-1-yl]-methanone;   (1H-Benzoimidazol-2-yl)-[3-(5-fluoro-3-phenyl-pyridin-2-yl)-azetidin-1-yl]-methanone;   (1H-benzoimidazol-2-yl)-[4-(3-phenyl-pyrazin-2-yl)-piperidin-1-yl]-methanone;   Benzothiazol-2-yl-[3-(3-phenyl-pyrazin-2-yl)-azetidin-1-yl]-methanone;   (1H-Benzoimidazol-2-yl)-[3-(3-piperidin-1-yl-quinoxalin-2-yl)-azetidin-1-yl]-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(4-hydroxy-piperidin-1-yl)-quinoxalin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-[3-(2,3-dihydro-indol-1-yl)-3′,4′,5′,6′-tetrahydro-2′H-[2,4′]bipyridinyl-1′-yl]-methanone;   (1H-Benzoimidazol-2-yl)-[3-(3-phenyl-quinolin-2-yl)-azetidin-1-yl]-methanone;   (1H-Benzoimidazol-2-yl)-(3-phenyl-3′,4′,5′,6′-tetrahydro-2′H-[2,4′]bipyridinyl-1′-yl)-methanone;   (1H-Benzoimidazol-2-yl)-{4-[3-(4-hydroxymethyl-piperidin-1-yl)-pyrazin-2-yl]-piperidin-1-yl}-methanone;   (3-(3-phenylpyrazin-2-yl)azetidin-1-yl)(pyridin-2-yl)methanone;   (6-methylpyridin-2-yl)(3-(3-phenylpyrazin-2-yl)azetidin-1-yl)methanone;   (3-methylpyridin-2-yl)(3-(3-phenylpyrazin-2-yl)azetidin-1-yl)methanone;   (5-methylpyridin-2-yl)(3-(3-phenylpyrazin-2-yl)azetidin-1-yl)methanone;   (4-methylpyridin-2-yl)(3-(3-phenylpyrazin-2-yl)azetidin-1-yl)methanone;   (1H-Benzoimidazol-2-yl)-[3-(3-phenyl-quinoxalin-2-yl)-azetidin-1-yl]-methanone;   (1H-Benzoimidazol-2-yl)-[3-(3-morpholin-4-yl-pyrazin-2-yl)-azetidin-1-yl]-methanone;   (1-Methyl-1H-benzoimidazol-2-yl)-[3-(3-phenyl-pyrazin-2-yl)-azetidin-1-yl]-methanone;   [3-(3-Phenyl-pyrazin-2-yl)-azetidin-1-yl]-[1-(2,2,2-trifluoro-ethyl)-1H-benzoimidazol-2-yl]-methanone;   (1H-Benzoimidazol-2-yl)-[3-(3-phenyl-pyrazin-2-yl)-azetidin-1-yl]-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(3,4-dimethoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(3-isopropyl-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(3-trifluoromethoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   1H-Benzoimidazol-2-yl)-{3-[3-(3,5-dimethoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(3-ethoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(3-isopropoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(3-fluoro-5-methoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(2-methoxy-pyridin-4-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(5-methoxy-pyridin-3-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-benzo[d]imidazol-2-yl)(3-(3-(4-fluoro-3-methylphenyl)pyrazin-2-yl)azetidin-1-yl)methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(4-methoxy-3-methyl-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(3-fluoro-5-methyl-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(5-methyl-pyridin-3-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(4-methyl-thiophen-2-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(1-methyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(3-hydroxymethyl-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(4-hydroxymethyl-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   1-(4-{3-[1-(1H-Benzoimidazole-2-carbonyl)-azetidin-3-yl]-pyrazin-2-yl}-phenyl)-ethanone;   1-(3-{3-[1-(1H-Benzoimidazole-2-carbonyl)-azetidin-3-yl]-pyrazin-2-yl}-phenyl)-ethanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(3-methoxymethyl-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   4-{3-[1-(1H-Benzoimidazole-2-carbonyl)-azetidin-3-yl]-pyrazin-2-yl}-N,N-dimethyl-benzamide;   3-{3-[1-(1H-Benzoimidazole-2-carbonyl)-azetidin-3-yl]-pyrazin-2-yl}-N,N-dimethyl-benzamide;   (1H-benzo[d]imidazol-2-yl)(3-(3-(pyridin-4-yl)pyrazin-2-yl)azetidin-1-yl)methanone;   (7-chloro-1H-benzo[d]imidazol-2-yl)(3-(3-(pyridin-3-yl)pyrazin-2-yl)azetidin-1-yl)methanone;   (1H-benzo[d]imidazol-2-yl)(3-(3-(2-methylpyridin-4-yl)pyrazin-2-yl)azetidin-1-yl)methanone;   (1H-benzo[d]imidazol-2-yl)(3-(3-(m-tolyl)pyrazin-2-yl)azetidin-1-yl)methanone;   3-(3-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yl)pyrazin-2-yl)benzonitrile   (1-Methyl-1H-benzoimidazol-2-yl)-[3-(3-piperidin-1-yl-pyrazin-2-yl)-azetidin-1-yl]-methanone;   {3-[3-(4-Hydroxy-piperidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-(1-methyl-1H-benzoimidazol-2-yl)-methanone;   [3-(3-Piperidin-1-yl-pyrazin-2-yl)-azetidin-1-yl]-[1-(2,2,2-trifluoro-ethyl)-1H-benzoimidazol-2-yl]-methanone;   {3-[3-(4-Hydroxy-piperidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-[1-(2,2,2-trifluoro-ethyl)-1H-benzoimidazol-2-yl]-methanone;   (1H-Benzoimidazol-2-yl)-[3-(3-pyrrolidin-1-yl-pyrazin-2-yl)-azetidin-1-yl]-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(4-trifluoromethyl-piperidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (R & S)-(1H-Benzoimidazol-2-yl)-{3-[3-(2-methyl-piperidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(3-methyl-piperidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(4-methyl-piperidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(4,4-dimethyl-piperidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(4-hydroxymethyl-piperidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-(3-{3-[4-(1-hydroxy-1-methyl-ethyl)-piperidin-1-yl]-pyrazin-2-yl}-azetidin-1-yl)-methanone;   (1H-Benzoimidazol-2-yl)-(3-{3-[4-(1-hydroxy-1-methyl-ethyl)-piperidin-1-yl]-pyrazin-2-yl}-azetidin-1-yl)-methanone;   1-{3-[1-(1H-Benzoimidazole-2-carbonyl)-azetidin-3-yl]-pyrazin-2-yl}-piperidine-4-carbonitrile;   (1H-Benzoimidazol-2-yl)-{3-[3-(4-methoxymethyl-piperidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (R & S)-(1H-Benzoimidazol-2-yl)-{3-[3-(3-methyl-pyrrolidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (R & S)-(1H-Benzoimidazol-2-yl)-{3-[3-(2-methyl-pyrrolidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(3,4-dihydro-1H-isoquinolin-2-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(1,3-dihydro-isoindol-2-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (R & S)-(1H-Benzoimidazol-2-yl)-{3-[3-(3-phenyl-pyrrolidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (R & S)-(1H-Benzoimidazol-2-yl)-{3-[3-(2-phenyl-pyrrolidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-[3-(3-cyclopentylamino-pyrazin-2-yl)-azetidin-1-yl]-methanone;   (1H-Benzoimidazol-2-yl)-[3-(3-cyclohexylamino-pyrazin-2-yl)-azetidin-1-yl]-methanone;   (1H-Benzoimidazol-2-yl)-[3-(3-benzylamino-pyrazin-2-yl)-azetidin-1-yl]-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(2-hydroxy-ethylamino)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-benzo[d]imidazol-2-yl)(3-(3-((2-methoxyethyl)amino)pyrazin-2-yl)azetidin-1-yl)methanone;   1-{3-[1-(1H-Benzoimidazole-2-carbonyl)-azetidin-3-yl]-pyrazin-2-yl}-piperidine-4-carboxylic acid amide;   (R & S)-(1H-Benzoimidazol-2-yl)-{3-[3-(3-hydroxymethyl-piperidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(3-hydroxy-piperidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   [3-(3-Azepan-1-yl-pyrazin-2-yl)-azetidin-1-yl]-(1H-benzoimidazol-2-yl)-methanone;   [3-(3-Azetidin-1-yl-pyrazin-2-yl)-azetidin-1-yl]-(1H-benzoimidazol-2-yl)-methanone;   (R)-(1H-Benzoimidazol-2-yl)-{3-[3-(2-hydroxymethyl-pyrrolidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-[3-(3-isopropylamino-pyrazin-2-yl)-azetidin-1-yl]-methanone;   (S)-(1H-Benzoimidazol-2-yl)-{3-[3-(2-hydroxymethyl-pyrrolidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-(3-{3-[4-(2-hydroxy-ethyl)-piperidin-1-yl]-pyrazin-2-yl}-azetidin-1-yl)-methanone;   (1H-Benzoimidazol-2-yl)-[3-(3-[1,4]oxazepan-4-yl-pyrazin-2-yl)-azetidin-1-yl]-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(4-methyl-[1,4]diazepan-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   1-(4-{3-[1-(1H-Benzoimidazole-2-carbonyl)-azetidin-3-yl]-pyrazin-2-yl}-[1,4]diazepan-1-yl)-ethanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(4-hydroxy-azepan-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (R & S)-(1H-Benzoimidazol-2-yl)-{3-[3-(3-hydroxymethyl-pyrrolidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (R)-(1H-Benzoimidazol-2-yl)-{3-[3-(3-hydroxy-piperidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (S)-(1H-Benzoimidazol-2-yl)-{3-[3-(3-hydroxy-piperidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (R & S)-1-{3-[1-(1H-Benzoimidazole-2-carbonyl)-azetidin-3-yl]-pyrazin-2-yl}-piperidine-3-carbonitrile;   1-{3-[1-(1H-Benzoimidazole-2-carbonyl)-azetidin-3-yl]-pyrazin-2-yl}-piperidine-4-carboxylic acid methylamide;   1-{3-[1-(1H-Benzoimidazole-2-carbonyl)-azetidin-3-yl]-pyrazin-2-yl}-piperidine-4-carboxylic acid dimethylamide;   1-(1-(3-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yl)pyrazin-2-yl)piperidin-4-yl)ethanone;   1-(4-(3-(1-(1H-benzo[d]imidazole-2-carbonyl)azetidin-3-yl)pyrazin-2-yl)piperazin-1-yl)ethanone;   (R)-(1H-benzo[d]imidazol-2-yl)(3-(3-(3-hydroxypyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)methanone;   (S)-(1H-benzo[d]imidazol-2-yl)(3-(3-(3-hydroxypyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)methanone;   (1H-benzo[d]imidazol-2-yl)(3-(3-(piperidin-1-yl)pyrazin-2-yl)azetidin-1-yl)methanone;   (1H-benzo[d]imidazol-2-yl)(3-(3-(4-hydroxypiperidin-1-yl)pyrazin-2-yl)azetidin-1-yl)methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(2-oxa-7-aza-spiro[3.5]non-7-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(2-oxa-6-aza-spiro[3.3]hept-6-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   1-(6-{3-[1-(1H-Benzoimidazole-2-carbonyl)-azetidin-3-yl]-pyrazin-2-yl}-2,6-diaza-spiro[3.3]hept-2-yl)-ethanone;   2-(3-(3-(2-methoxypyridin-3-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(6-methylpyridin-3-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(2-methylpyridin-3-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(6-fluoropyridin-3-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(2,6-dimethoxypyridin-3-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(5-fluoropyridin-3-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(6-methoxypyridin-3-yl)pyrazin-2-yl)azetidin-1-yl)quinoline2,2,2-trifluoroacetate;   2-(3-(3-(6-fluoro-5-methylpyridin-3-yl)pyrazin-2-yl)azetidin-1-yl)quinoline2,2,2-trifluoroacetate;   2-(3-(3-(pyridin-3-yl)pyrazin-2-yl)azetidin-1-yl)quinoline2,2,2-trifluoroacetate;   2-(3-(3-(4-(methylsulfonyl)phenyl)pyrazin-2-yl)azetidin-1-yl)quinoline2,2,2-trifluoroacetate;   5-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyridin-2-amine;   5-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyridin-3-amine;   2-(3-(3-(6-methoxypyridin-2-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(2-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)azetidin-1-yl)quinoline2,2,2-trifluoroacetate;   N,N-dimethyl-5-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrimidin-2-amine2,2,2-trifluoroacetate;   2-(3-(3-(4-methylpyridin-3-yl)pyrazin-2-yl)azetidin-1-yl)quinoline2,2,2-trifluoroacetate;   2-(3-(3-(5-(methylsulfonyl)pyridin-3-yl)pyrazin-2-yl)azetidin-1-yl)quinoline2,2,2-trifluoroacetate;   2-(3-(3-(5-methylpyridin-3-yl)pyrazin-2-yl)azetidin-1-yl)quinoline2,2,2-trifluoroacetate;   2-(3-(3-(5-methoxypyridin-3-yl)pyrazin-2-yl)azetidin-1-yl)quinoline2,2,2-trifluoroacetate;   2-(3-(3-(4-chloro-3-methylphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3-fluoro-4-methylphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-chloro-4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)phenol;   2-(3-(3-(3-methoxy-5-(trifluoromethyl)phenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(4-ethoxy-3-fluorophenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3-chloro-4-ethoxyphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3-chloro-4-propoxyphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3-fluoro-5-(trifluoromethyl)phenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(4-methoxy-3-methylphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3-fluoro-5-isopropoxyphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3-fluoro-5-methylphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3-chloro-4-fluorophenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3,4-difluorophenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3,4-dichlorophenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3,4-dimethylphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3-chloro-4-methylphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3-chloro-5-methylphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(4-fluoro-3-methylphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(pyrimidin-5-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(4-chloro-3-(trifluoromethyl)phenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3,6-dihydro-2H-pyran-4-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(2,2-dimethyl-3,6-dihydro-2H-pyran-4-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(6,6-dimethyl-3,6-dihydro-2H-pyran-4-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(1H-pyrazol-4-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3-fluoro-5-(trifluoromethyl)phenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(6-methoxypyridin-2-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-phenylpyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(4-methoxyphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(4-fluorophenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(2-fluorophenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3-fluorophenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(pyridin-4-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   3-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)benzonitrile;   4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)benzonitrile;   methyl 3-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)benzoate;   ethyl 4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)benzoate;   2-(3-(3-(2-methoxypyridin-4-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(2-fluoropyridin-4-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3-(methylthio)phenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   1-(4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)phenyl)ethanone;   2-(3-(3-(4-phenoxyphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3-fluoro-4-methoxyphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   N,N-dimethyl-3-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)aniline;   N-methyl-3-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)benzamide;   tert-butyl 4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate;   2-(3-(3-([1,1′-biphenyl]-3-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-fluoro-4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)benzonitrile;   2-fluoro-5-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)benzonitrile;   N,N-dimethyl-3-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)benzamide;   2-(3-(3-(2-methoxyphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3-(trifluoromethyl)phenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3-ethoxyphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   1-(3-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)phenyl)ethanone;   (3-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)phenyl)methanol;   2-(3-(3-(3-(trifluoromethoxy)phenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3-(benzyloxy)phenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   N-cyclopropyl-3-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)benzamide;   N,N-dimethyl-3-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)benzenesulfonamide;   2-(3-(3-(4-ethoxyphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   (4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)phenyl)methanol;   2-(3-(3-(4-propylphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(4-ethylphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   N,N-dimethyl-4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)aniline;   2-(3-(3-(4-(trifluoromethoxy)phenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(4-isopropoxyphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-methyl-2-(4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)phenyl)propanenitrile;   4-((4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)phenyl)sulfonyl)morpholine;   2-(3-(3-(4-(piperidin-1-ylsulfonyl)phenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   (R— & S—)-2-(3-(3-(3-(pyridin-3-yl)pyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   (R— & S—)-2-(3-(3-(3-phenethylpyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   (R— & S—)-2-(3-(3-(3-benzylpyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   (R)—N,N-dimethyl-1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-3-amine;   (R— & S—)-tert-butyl methyl(1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-3-yl)carbamate;   (R— & S—)-N,N-dimethyl-1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-3-amine;   2-(3-(3-(3-azabicyclo[3.1.0]hexan-3-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   (R— & S—)-2-(3-(3-(3-(phenylsulfonyl)pyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   (R— & S—)-3-methyl-5-(1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-3-yl)-1,2,4-oxadiazole;   (R)-1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-3-ol;   (R— & S—)-2-(3-(3-(3-(pyridin-4-yl)pyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(pyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   (3aR,6aS)-tert-butyl 5-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate;   tert-butyl 5-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate;   tert-butyl 4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)-1,4-diazepane-1-carboxylate;   (R)-(1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-3-yl)methanol;   (R— & S—)-2-(3-(3-(3-(methylsulfonyl)pyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   (S)-(1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-3-yl)methanol;   (R)-tert-butyl 1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-3-ylcarbamate;   (S)-2-(3-(3-(3-fluoropyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3,3-difluoropyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(4-isopropyl-1,4-diazepan-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   (1R,5R)-3-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)-3-azabicyclo[3.2.2]nonane;   2-(3-(3-(azepan-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(4-methyl-1,4-diazepan-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   3-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)-3-azabicyclo[3.2.2]nonane;   1-(4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)-1,4-diazepan-1-yl)ethanone;   (R— & S—)-2-(3-(3-(3-phenylpyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   (3S,4S)-1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidine-3,4-diol;   N-(4-methoxybenzyl)-3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-amine;   (1R,4R)-5-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)-2-oxa-5-azabicyclo[2.2.1]heptanes;   (R— & S—)-2-(1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-3-yl)thiazole;   (S)-(1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-2-yl)methanol;   ((2S,4S)-4-fluoro-1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-2-yl)methanol;   (R)-2-(3-(3-(2-(methoxymethyl)pyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   (R— & S—)-2-(3-(3-(3-isobutylpyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3,3-dimethylpyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   (R— & S—)-2-(3-(3-(3-(methoxymethyl)pyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(4-(trifluoromethyl)piperidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)piperidine-4-carbonitrile;   2-(3-(3-(4,4-difluoropiperidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)morpholine;   2-(3-(3-(4-fluoropiperidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3-methoxyazetidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(3-(3-(3,3-difluoroazetidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   4-methyl-1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)piperidin-4-ol;   1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)-1H-pyrazole-4-carbonitrile   2-(3-(3-(4-methyl-1H-pyrazol-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   tert-butyl (1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)azetidin-3-yl)carbamate;   2,2-dimethyl-4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)morpholine;   2-(3-(3-(4-methyl-1H-imidazol-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   1-(3-(1-(quinazolin-2-yl)azetidin-3-yl)pyrazin-2-yl)piperidine-4-carbonitrile;   (1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)-1H-pyrazol-4-yl)methanol;   (1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)-1H-imidazol-4-yl)methanol;   1-methyl-4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)piperazin-2-one;   N-(2,6-dimethylphenyl)-1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)piperidine-3-carboxamide;   (S)-tert-butyl (1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)piperidin-3-yl)carbamate;   (4-(cyclopropylmethyl)-1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)piperidin-4-yl)methanol;   2-(3-(3-((1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-3-amine;   (R— & S—)-methyl (1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-3-yl)carbamate;   (R— & S—)—N-(1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-3-yl)methanesulfonamide;   (R— & S—)-ethyl (1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-3-yl)carbamate;   (R— & S—)-2-methoxy-N-(1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-3-yl)acetamide;   2-(3-(3-(1,4-Diazepan-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   Methyl 4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)-1,4-diazepane-1-carboxylate;   methyl methyl(1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-3-yl)carbamate;   N-methyl-N-(1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-3-yl)methanesulfonamide;   Ethyl methyl(1-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)pyrrolidin-3-yl)carbamate;   2-(3-(3-(4-chlorophenyl)pyrazin-2-yl)azetidin-1-yl)quinazoline;   2-(3-(3-(3-chlorophenyl)pyrazin-2-yl)azetidin-1-yl)quinazoline;   2-(3-(3-(2-chlorophenyl)pyrazin-2-yl)azetidin-1-yl)quinazoline;   2-(3-(3-(o-tolyl)pyrazin-2-yl)azetidin-1-yl)quinazoline;   1-(4-(3-(1-(quinazolin-2-yl)azetidin-3-yl)pyrazin-2-yl)phenyl)ethanone;   1-(3-(3-(1-(quinazolin-2-yl)azetidin-3-yl)pyrazin-2-yl)phenyl)ethanone;   N-(3-(3-(1-(quinazolin-2-yl)azetidin-3-yl)pyrazin-2-yl)phenyl)acetamide;   N-(4-(3-(1-(quinazolin-2-yl)azetidin-3-yl)pyrazin-2-yl)phenyl)methanesulfonamide;   N-(3-(3-(1-(quinazolin-2-yl)azetidin-3-yl)pyrazin-2-yl)phenyl)methanesulfonamide;   2-(3-(3-(1H-indol-6-yl)pyrazin-2-yl)azetidin-1-yl)quinazoline;   2-(3-(3-(1-methyl-1H-indol-5-yl)pyrazin-2-yl)azetidin-1-yl)quinazoline;   2-(3-(3-(1-methyl-1H-indol-6-yl)pyrazin-2-yl)azetidin-1-yl)quinazoline;   5-(3-(1-(quinazolin-2-yl)azetidin-3-yl)pyrazin-2-yl)indolin-2-one;   1-methyl-5-(3-(1-(quinazolin-2-yl)azetidin-3-yl)pyrazin-2-yl)indolin-2-one;   1-methyl-6-(3-(1-(quinazolin-2-yl)azetidin-3-yl)pyrazin-2-yl)-1H-benzo[d]imidazol-2(3H)-one;   2-fluoro-4-(3-(1-(quinazolin-2-yl)azetidin-3-yl)pyrazin-2-yl)aniline;   2-(3-(3-(p-tolyl)pyrazin-2-yl)azetidin-1-yl)quinazoline;   2-methyl-6-(3-(1-(quinazolin-2-yl)azetidin-3-yl)pyrazin-2-yl)isoquinolin-1(2H)-one;   2-(3-(3-(1H-indazol-5-yl)pyrazin-2-yl)azetidin-1-yl)quinazoline;   5-(3-(1-(quinazolin-2-yl)azetidin-3-yl)pyrazin-2-yl)benzo[d]thiazole;   (R & S)-(1H-Benzoimidazol-2-yl)-(3-{3-[4-(1-hydroxy-ethyl)-phenyl]-pyrazin-2-yl}-azetidin-1-yl)-methanone;   (R & S)-(1H-Benzoimidazol-2-yl)-(3-{3-[3-(1-hydroxy-ethyl)-phenyl]-pyrazin-2-yl}-azetidin-1-yl)-methanone;   (R & S)-(1H-Benzoimidazol-2-yl)-(3-{3-[4-(1-hydroxy-ethyl)-piperidin-1-yl]-pyrazin-2-yl}-azetidin-1-yl)-methanone;   1-(4-{3-[1-(1H-Benzoimidazole-2-carbonyl)-azetidin-3-yl]-pyrazin-2-yl}-piperidin-1-yl)-ethanone;   1-{3-[1-(1H-Benzoimidazole-2-carbonyl)-azetidin-3-yl]-pyrazin-2-yl}-piperidin-4-one;   (1H-Benzoimidazol-2-yl)-{3-[3-(4,4-difluoro-piperidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(4-hydroxy-4-methyl-piperidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-[3-(5-phenyl-pyrimidin-4-yl)-azetidin-1-yl]-methanone;   2-(3-(3-(prop-1-yn-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-[3-(3-m-Tolyl-pyrazin-2-yl)-azetidin-1-yl]-quinoline;   2-[3-(3-m-Tolyl-pyrazin-2-yl)-azetidin-1-yl]-quinazoline;   2-[3-(3-m-Tolyl-pyrazin-2-yl)-azetidin-1-yl]-quinoxaline;   2-[3-(3-m-Tolyl-pyrazin-2-yl)-azetidin-1-yl]-benzothiazole;   2-{3-[3-(3-Methoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-quinoline;   2-{3-[3-(3-Methoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-quinazoline;   2-{3-[3-(3-Methoxy-phenyl)-pyridin-2-yl]-azetidin-1-yl}-quinoline;   2-[3-(3-m-Tolyl-pyridin-2-yl)-azetidin-1-yl]-quinoline;   (R & S)-2-{3-[3-(3-Methyl-pyrrolidin-1-yl)-pyridin-2-yl]-azetidin-1-yl}-quinoline;   4-Methyl-2′-(1-quinolin-2-yl-azetidin-3-yl)-3,4,5,6-tetrahydro-2H-[1,3′]bipyridinyl;   {1-[3-(1-Quinolin-2-yl-piperidin-4-yl)-pyrazin-2-yl]-piperidin-4-yl}-methanol;   {1-[3-(1-Quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-piperidin-4-yl}-methanol;   {1-[3-(1-Quinazolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-piperidin-4-yl}-methanol;   4-[3-(1-Quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-phenylamine;   {1-[3-(1-Benzothiazol-2-yl-azetidin-3-yl)-pyrazin-2-yl]-piperidin-4-yl}-methanol;   {1-[3-(1-Benzooxazol-2-yl-azetidin-3-yl)-pyrazin-2-yl]-piperidin-4-yl-methanol;   (1-{3-[1-(5-Methyl-pyridin-2-yl)-azetidin-3-yl]-pyrazin-2-yl}-piperidin-4-yl)-quinoline;   2-(4-benzylpiperidin-1-yl)-3-(1-(quinolin-2-yl)azetidin-3-yl)quinoxaline;   [5′-Fluoro-2′-(1-quinolin-2-yl-azetidin-3-yl)-3,4,5,6-tetrahydro-2H-[1,3′]bipyridinyl-4-yl]-quinoline;   {1-[3-(1-Quinolin-2-yl-azetidin-3-yl)-pyridazin-4-yl]-piperidin-4-yl}-quinoline;   (R & S)-2-(3-(3-(3-methylpyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   (S or R)-2-(3-(3-(3-methylpyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   (R or S)-2-(3-(3-(3-methylpyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   2-(1-Quinolin-2-yl-azetidin-3-yl)-3-m-tolyl-quinoxaline;   4-[3-(1-Quinolin-2-yl-azetidin-3-yl)-quinoxalin-2-yl]-phenylamine;   3-[3-(1-Quinolin-2-yl-azetidin-3-yl)-quinoxalin-2-yl]-phenol;   2-(3-Methoxy-phenyl)-3-(1-quinolin-2-yl-azetidin-3-yl)-quinoxaline;   2-[3-(1-Quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-phenol;   3-[3-(1-Quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-phenol;   4-[3-(1-Quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-phenol;   2-[3-(1-Quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-phenylamine;   3-[3-(1-Quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-phenylamine;   4-[3-(1-Quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-phenylamine;   2-{3-[3-(4-Fluoro-3-methoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-quinoline;   2-Fluoro-4-[3-(1-quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-phenylamine   2-[3-(3-Piperidin-1-yl-pyrazin-2-yl)-azetidin-1-yl]-quinoline;   2-{3-[3-(4-Methyl-piperidin-1-yl)-pyrazin-2-yl]-azetidin-1-yl}-quinoline;   1-[3-(1-Quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-piperidine-4-carboxylic acid amide;   1-[3-(1-Quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-piperidine-4-carboxylic acid dimethylamide;   1-[3-(1-Quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-piperidine-4-carboxylic acid methylamide;   1-[3′-(1-Quinolin-2-yl-azetidin-3-yl)-2,3,5,6-tetrahydro-[1,2′]bipyrazinyl-4-yl]-ethanone;   1-[3-(1-Quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-piperidin-4-ol;   2-Methoxy-1-{4-[3-(1-quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-piperidin-1-yl}-ethanone;   1-{4-[3-(1-Quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-piperidin-1-yl}-ethanone;   N-{4-[3-(1-Quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-phenyl}-acetamide;   1-(4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone;   (R & S)-1-{1-[3-(1-Quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-piperidin-4-yl}-ethanol;   (R or S, absolute stereospecificity not determined)-1-{1-[3-(1-Quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-piperidin-4-yl}-ethanol;   (S or R, absolute stereospecificity not determined)-1-{1-[3-(1-Quinolin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-piperidin-4-yl}-ethanol;   2-fluoro-5-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)phenol;   (1-{3-[1-(6-Methyl-quinolin-2-yl)-azetidin-3-yl]-pyrazin-2-yl}-piperidin-4-yl)-quinoline;   (1-{3-[1-(7-Fluoro-quinolin-2-yl)-azetidin-3-yl]-pyrazin-2-yl}-piperidin-4-yl)-quinoline;   (1-{3-[1-(6-Fluoro-quinolin-2-yl)-azetidin-3-yl]-pyrazin-2-yl}-piperidin-4-yl)-quinoline;   {1-[3-(1-[1,8]Naphthyridin-2-yl-azetidin-3-yl)-pyrazin-2-yl]-piperidin-4-yl}-quinoline;   (1-{3-[1-(6-Chloro-quinolin-2-yl)-azetidin-3-yl]-pyrazin-2-yl}-piperidin-4-yl)-quinoline;   (1-{3-[1-(6-Chloro-quinoxalin-2-yl)-azetidin-3-yl]-pyrazin-2-yl}-piperidin-4-yl)-quinoline;   (1-{3-[1-(6-Methyl-pyridin-2-yl)-azetidin-3-yl]-pyrazin-2-yl}-piperidin-4-yl)-quinoline;   (1-{3-[1-(5-Chloro-pyridin-2-yl)-azetidin-3-yl]-pyrazin-2-yl}-piperidin-4-yl)-quinoline;   (1-(3-(1-(5-bromopyridin-2-yl)azetidin-3-yl)pyrazin-2-yl)piperidin-4-yl)quinoline;   (1-(3-(1-(8-methylquinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)piperidin-4-yl)quinoline;   (1-{3-[1-(8-Fluoro-quinolin-2-yl)-azetidin-3-yl]-pyrazin-2-yl}-piperidin-4-yl)-quinoline;   (1-(3-(1-(8-chloroquinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)piperidin-4-yl)quinoline;   (1-{3-[1-(8-Chloro-quinazolin-2-yl)-azetidin-3-yl]-pyrazin-2-yl}-piperidin-4-yl)-quinoline;   (1-{3-[1-(7-Chloro-quinazolin-2-yl)-azetidin-3-yl]-pyrazin-2-yl}-piperidin-4-yl)-quinoline;   (1-{3-[1-(6-Chloro-quinazolin-2-yl)-azetidin-3-yl]-pyrazin-2-yl}-piperidin-4-yl)-quinoline;   (1-{3-[1-(5-Chloro-quinazolin-2-yl)-azetidin-3-yl]-pyrazin-2-yl}-piperidin-4-yl)-quinoline;   (1-{3-[1-(7-Chloro-quinoxalin-2-yl)-azetidin-3-yl]-pyrazin-2-yl}-piperidin-4-yl)-quinoline;   2-[3-(3-Piperidin-1-yl-pyrazin-2-yl)-azetidin-1-yl]-benzothiazole;   2-(3-(3-(3-methoxyphenyl)pyrazin-2-yl)azetidin-1-yl)-8-methylquinoline;   6-Chloro-2-{3-[3-(3-methoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-quinazoline   8-Chloro-2-{3-[3-(3-methoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-quinoline;   7-Fluoro-2-{3-[3-(3-methoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-quinoline;   2-{3-[3-(3-Methoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-6-methyl-quinoline;   2-{3-[3-(3-Methoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-[1,8]naphthyridine;   8-Chloro-2-{3-[3-(3-methoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-quinazoline;   5-Chloro-2-{3-[3-(3-methoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-quinazoline;   2-(3-(3-(3-methoxyphenyl)pyrazin-2-yl)azetidin-1-yl)-4-phenylpyrimidine;   2-(3-(3-(3-methoxyphenyl)pyrazin-2-yl)azetidin-1-yl)benzo[d]thiazole;   6-methoxy-2-(3-(3-(3-methoxyphenyl)pyrazin-2-yl)azetidin-1-yl)benzo[d]thiazole;   2-(3-(3-(3-methoxyphenyl)pyrazin-2-yl)azetidin-1-yl)-1,6-naphthyridine;   6-chloro-2-(3-(3-(3-methoxyphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline;   6-fluoro-2-(3-(3-(3-methoxyphenyl)pyrazin-2-yl)azetidin-1-yl)benzo[d]thiazole;   2-(3-(3-(3-methoxyphenyl)pyrazin-2-yl)azetidin-1-yl)quinoline; -3-carbonitrile;   1-[3-(3-Phenyl-pyrazin-2-yl)-azetidin-1-yl]-phthalazine;   6-chloro-2-(3-(3-phenylpyrazin-2-yl)azetidin-1-yl)-1H-benzo[d]imidazole;   2-(3-(3-phenylpyrazin-2-yl)azetidin-1-yl)-1H-benzo[d]imidazole;   2-((3-(3-phenylpyrazin-2-yl)azetidin-1-yl)methyl)-1H-benzo[d]imidazole;   3-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)benzamide;   4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)benzamide;   2-fluoro-5-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)benzamide;   2-fluoro-4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)benzamide;   2-(3-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)phenyl)propan-2-ol;   2-(4-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)phenyl)propan-2-ol;   2-(3-(3-(1,2,3,6-tetrahydropyridin-4-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   lithium 3-(3-(1-(quinolin-2-yl)azetidin-3-yl)pyrazin-2-yl)benzoate;   (S or R)-2-(3-(3-(3-(pyridin-3-yl)pyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   (R or S)-2-(3-(3-(3-(pyridin-3-yl)pyrrolidin-1-yl)pyrazin-2-yl)azetidin-1-yl)quinoline;   (1H-Benzoimidazol-2-yl)-{3-[3-(2-methoxy-phenoxy)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(3-methoxy-phenoxy)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-benzoimidazol-2-yl)-{3-[3-(4-methoxy-phenoxy)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-[3-(3-phenoxy-pyrazin-2-yl)-azetidin-1-yl]-methanone;   (1H-benzoimidazol-2-yl)-{3-[3-(tetrahydro-pyran-4-yl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (7-Chloro-1H-benzoimidazol-2-yl)-[3-(3-phenyl-pyrazin-2-yl)-azetidin-1-yl]-methanone;   (6-Chloro-1H-benzoimidazol-2-yl)-[3-(3-phenyl-pyrazin-2-yl)-azetidin-1-yl]-methanone;   (7-Fluoro-1H-benzoimidazol-2-yl)-[3-(3-phenyl-pyrazin-2-yl)-azetidin-1-yl]-methanone;   (6-Fluoro-1H-benzoimidazol-2-yl)-[3-(3-phenyl-pyrazin-2-yl)-azetidin-1-yl]-methanone;   (6-methyl-1H-benzoimidazol-2-yl)-[3-(3-phenyl-pyrazin-2-yl)-azetidin-1-yl]-methanone;   (6-methyl-1H-benzoimidazol-2-yl)-[3-(3-phenyl-pyrazin-2-yl)-azetidin-1-yl]-methanone;   (1H-benzoimidazol-2-yl)-{3-[3-(2-methoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-benzoimidazol-2-yl)-{3-[3-(3-methoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-Benzoimidazol-2-yl)-{3-[3-(4-methoxy-phenyl)-pyrazin-2-yl]-azetidin-1-yl}-methanone;   (1H-benzoimidazol-2-yl)-[3-(2-phenyl-pyridin-3-yl)-azetidin-1-yl]-methanone; or   2-(3-(3-(1H-indol-5-yl)pyrazin-2-yl)azetidin-1-yl)quinazoline.